Protective effect of docosahexaenoic acid against development of hypertension in young stroke-prone spontaneously hypertensive rats. Focus on the sympathoadrenal system and lipid metabolism

Abstract

The present study was undertaken to elucidate the effects of acute and subacute administration of docosahexaenoic acid (DHA) on blood pressure in SHRSP between the ages of 6 and 11 weeks. The continuous administration of DHA for 5 weeks in SHRSP significantly inhibited blood pressure rise as compared with levels in non-treated SHRSP. DHA-treated SHRSP showed significantly decreased urinary epinephrine contents as compared with those in non-treated SHRSP. DHA-treated SHRSP produced a significant decrease in adrenal epinephrine concentration as compared with those in non-treated SHRSP at the age of 11 weeks. DHA-treated SHRSP also demonstrated significant decreases in serum triglycerides, LDL and lipid peroxide levels as compared with levels in non-treated SHRSP. However, a single intraperitoneal administration of DHA did not exert any influence on blood pressure in SHRSP at the age of 11 weeks. These findings suggest that the anti-hypertensive effect induced by a 5-week, continuous administration of DHA appears to be associated with the amelioration of increased sympathoadrenal activity and serum lipid derangement during the developmental stage of hypertension in young SHRSP.The present study clarified that a 5-week, continuous administration of DHA had a protective effect against the development of hypertension in SHRSP.